HANDBOOK OF PHARMACY AND THERAPEUTICS

By U. MAVAO

CONTENTS TARGETING TYPE 2 DIABETES DUAL ACTING AND PAN-PPAR ACTIVATORS AS POTENTIAL ANTI-DIABETIC THERAPIES GLP-1 AGONISTS AND DIPEPTIDYL-PEPTIDASE IV INHIBITORS CANNABINOIDS AND ENDOCANNABINOIDS IN METABOLIC DISORDERS WITH FOCUS ON DIABETES SGLT INHIBITORS AS NEW THERAPEUTIC TOOLS IN THE TREATMENT OF DIABETES INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE TYPE IN ANTIDIABETIC THERAPY NAMPT AND ITS POTENTIAL ROLE IN IN?AMMATION AND TYPE 2 DIABETES ¨ INHIBITION OF GANGLIOSIDE BIOSYNTHESIS AS A NOVEL THERAPEUTIC APPROACH IN INSULIN RESISTANCE OVERCOMING INSULIN RESISTANCE WITH CILIARY NEUROTROPHIC FACTOR THERMOGENESIS AND RELATED METABOLIC TARGETS IN ANTI-DIABETIC THERAPY INTERLEUKIN-TARGETED THERAPY FOR METABOLIC SYNDROME AND TYPE 2 DIABETES FRUCTOSE-1, 6-BISPHOSPHATASE INHIBITORS FOR REDUCING EXCESSIVE ENDOGENOUS GLUCOSE PRODUCTION IN TYPE 2 DIABETES AMP-ACTIVATED PROTEIN KINASE AND METABOLIC CONTROL MITOCHONDRIA AS POTENTIAL TARGETS IN ANTIDIABETIC THERAPY RESEARCH AND DEVELOPMENT OF GLUCOKINASE ACTIVATORS FOR DIABETES THERAPY: THEORETICAL AND PRACTICAL ASPECTS TARGETING TYPE 2 DIABETES IN?AMED ABOUT OBESITY: ADIPOSE TISSUE AND INSULIN RESISTANCE THE LIPOTOXICITY CONCEPT B-CELL FAILURE: LINK TO HYPERGLYCAEMIA AND T2DM ROLE OF THE CNS IN GLUCOSE HOMEOSTASIS NUTRIENT-SENSING PATHWAYS IN CALORIE RESTRICTION CURRENT THERAPY PUBLISHED ALGORITHMS METFORMIN THIAZOLIDINEDIONES GLP-1 AGONISTS AND DPP-4 INHIBITORS CONCLUSIONS REFERENCES